The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Combinatorial cellular therapy in pediatric solid tumors with natural killer (NK) and genetically engineered myeloid cells (GEMys).
 
Kathy Pei Li
No Relationships to Disclose
 
James Cronk
No Relationships to Disclose
 
Sabina Kaczanowska
Patents, Royalties, Other Intellectual Property - PCT/US2023/078854; PCT/US2023/066025; PCT/US2020/17515
 
Marcelo Pereira
Stock and Other Ownership Interests - Fate therapeutics; Johnson & Johnson/Janssen; Merck; Moderna Therapeutics
Patents, Royalties, Other Intellectual Property - Intellectual Property Rights (License / Royalties paid directly to individual directly or through the NCH Research Institute)
 
Noriko Sato
No Relationships to Disclose
 
Robin Nakkula
No Relationships to Disclose
 
Yun Chen
No Relationships to Disclose
 
Peter Choyke
No Relationships to Disclose
 
Dean Anthony Lee
Stock and Other Ownership Interests - Avidicure
Consulting or Advisory Role - Avidicure; Kiadis Pharma
Research Funding - Avidicure; Kiadis Pharma
Patents, Royalties, Other Intellectual Property - Over a dozen patent families involving NK cell therapeutics licensed to Kiadis Pharma through Nationwide Children's Hospital.
Travel, Accommodations, Expenses - Cyto-Sen Therapeutics; Merck Sharp & Dohme; Shire
 
Rosandra N. Kaplan
No Relationships to Disclose